Hereditary Angioedema Prophylaxis: Persistence and Adherence

Advances in hereditary angioedema attack prophylaxis have provided more options for patients than ever before, with multiple agents available for long-term prevention. "The treatment landscape for hereditary angioedema is evolving rapidly, with several long-term prophylaxes approved in the last decade," and more on the horizon, said William Lumry, MD, of AARA Research Center in Dallas. "Over time the treatment burden has gone down significantly. ... And now we're starting to see more extended-interval drugs." These preventive medications include:C1 esterase inhibitor (Haegarda) approved in 2017 for subcutaneous injection every 3-4 daysPlasma kallikrein inhibitor lanadelumab (Takhzyro) approved in 2018 for subcutaneous injection every 2-4 weeksPlasma kallikrein inhibitor berotralstat (Orladeyo) approved in 2020 as a once-daily oral capsuleAnti-factor XIIa biologic garadacimab (Andembry) approved in 2025 for subcutaneous injection once monthlyRNA-targeted therapy donidalorsen (Dawnzera) approved in 2025 for subcutaneous injection every 4 or 8 weeks And real-world data show that patients are taking advantage of those options, sticking with a medication typically less than 2 years. Those were the findings Lumry reported from an observational study presented in March at the American Academy of Allergy, Asthma & Immunology annual meeting. His analysis of the Komodo Research Database of insurance claims to more than 150